Guidance

References

Updated 19 March 2025

漏 Crown copyright 2025

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at /government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control/references

  1. Liu FH, Z-D, Zhao X-M, Zhao W-N, Feng Z-X, Yurko, A, Alwasel S, Boekhout T, Bensch K, Hui F-L, Bai F-Y, Wang Q-M. 鈥楶hylogenomic analysis of the Candida auris-Candida haemuli clade and related taxa in the Metschnikowiaceae, and proposal of 13 new genera, 55 new combinations and 9 new species鈥� Persoonia - Molecular Phylogeny and Evolution of Fungi 2024: volume 52, pages 22 to 43
  2. Jones CR, Neill C, Borman AM, Budd EL, Cummins M, Fry C and others. 鈥楾he laboratory investigation, management, and infection prevention and control of Candida auris: a narrative review to inform the 2024 national guidance update in England鈥� Journal of Medical Microbiology 2024: volume 73, issue 5
  3. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 鈥楥andida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital鈥� Microbiology and Immunology 2009: volume 53, issue 1, pages 41 to 44
  4. Fisher MC, Denning DW. 鈥楾he WHO fungal priority pathogens list as a game-changer鈥� Nature Reviews Microbiology 2023: volume 21, issue 4, pages 211 to 212
  5. Dang T, Bassett J, Souri A, Nutt A, Honza H, Retana D and others. 鈥楾ransmission of pan-resistant and echinocandin-resistant Candida auris between healthcare facilities during the COVID-19 pandemic鈥� American Journal of Infection Control 2022: volume 50, 7 supplement, S2 to S3
  6. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K and others. 鈥楥ontrolling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions鈥� Journal of Hospital Infections 2017: volume 97, issue 4, pages 363 to 370
  7. Sansom SE, Gussin GM, Schoeny M, Singh RD, Adil H, Bell P and others. 鈥楻apid environmental contamination With Candida auris and multidrug-resistant bacterial pathogens near colonized patients鈥� Clinical Infectious Diseases 2024: volume 78, issue 5, pages 1,276 to 1,284
  8. Bergeron G, Bloch D, Murray K, Kratz M, Parton H, Ackelsberg J and others. 鈥楥andida auris colonization after discharge to a community setting: New York City 2017 to 2019鈥� Open Forum Infectious Diseases 2021: volume 8, issue 1, page ofaa620
  9. Rossow J, Ostrowsky B, Adams E, Greenko J, McDonald R, Vallabhaneni S and others. 鈥楩actors associated with Candida auris colonization and transmission in skilled nursing facilities with ventilator units, New York 2016 to 2018鈥� Clinical Infectious Diseases 2021: 72, issue 11, pages e753 to e60
  10. Hu S, Zhu F, Jiang W, Wang Y, Quan Y, Zhang G and others. 鈥楻etrospective analysis of the clinical characteristics of Candida auris infection worldwide from 2009 to 2020鈥� Frontiers in Microbiology 2021: volume 12, page 658,329
  11. Alvarez-Moreno CA, Morales-L贸pez S, Rodriguez GJ, Rodriguez JY, Robert E, Picot C and others. 鈥楾he mortality attributable to Candidemia in C. auris Is higher than that in other candida species: myth or reality?鈥� Journal of Fungi (Basel) 2023: volume 9, issue 4
  12. Forg谩cs L, Borman AM, Pr茅post E, T贸th Z, Kardos G, Kov谩cs R and others. 鈥楥omparison of in vivo pathogenicity of 4 Candida auris clades in a neutropenic bloodstream infection murine model鈥� Emerging Microbes and Infections 2020: volume 9, issue 1, pages 1,160 to 1,169
  13. Borman AM, Johnson EM. 鈥楥andida auris in the UK: Introduction, dissemination and control鈥� PLoS Pathogens 2020: volume 16, issue 7, article e1008563
  14. Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP and others. 鈥楢 Candida auris outbreak and its control in an intensive care setting鈥� New England Journal of Medicine 2018: volume 379, issue 14, pages 1,322 to 1,331
  15. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A and others. 鈥楩irst hospital outbreak of the globally emerging Candida auris in a European hospital鈥� Antimicrobial Resistance and Infection Control 2016: volume 5, issue 35
  16. Taori SK, Khonyongwa K, Hayden I, Athukorala GDA, Letters A, Fife A and others. 鈥楥andida auris outbreak: mortality, interventions and cost of sustaining control鈥� Journal of Infection 2019: volume 79, issue 6, pages 601 to 611
  17. Taori SK, Rhodes J, Khonyongwa K, Szendroi A, Smith M, Borman AM and others. 鈥楩irst experience of implementing Candida auris real-time PCR for surveillance in the UK: detection of multiple introductions with two international clades and improved patient outcomes鈥� Journal of Hosp Infections 2022: volume 127, pages 111 to 120
  18. Borman AM, Fraser M, Johnson EM. 鈥楥HROMagar鈩� Candida Plus: a novel chromogenic agar that permits the rapid identification of Candida auris鈥� Medical Mycology 2021: volume 59, issue 3, pages 253 to 258
  19. de Jong AW, Dieleman C, Carbia M, Mohd Tap R, Hagen F. 鈥楶erformance of 2 novel chromogenic media for the identification of multidrug-resistant Candida auris compared with other commercially available formulations鈥� Journal of Clinical Microbiology 2021: volume 59, issue 4
  20. Abdolrasouli A, Fraser MA. 鈥楥andida auris identification and profiling by MALDI-ToF mass spectrometry鈥� Methods in Molecular Biology 2022: volume 2,517, pages 21 to 32
  21. Leach L, Zhu Y, Chaturvedi S. 鈥楧evelopment and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples鈥� Journal of Clinical Microbiology 2018: volume 56, issue 2
  22. Lyman M, Forsberg K, Sexton DJ, Chow NA, Lockhart SR, Jackson BR and others. 鈥榃orsening spread of Candida auris in the United States, 2019 to 2021鈥� Annals of Internal Medicie 2023: volume 176, issue 4, pages 489 to 495
  23. Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D and others. 鈥楥andida auris pan-drug-resistant to 4 classes of antifungal agents鈥� Antimicrobial Agents and Chemotherapy 2022: volume 66,. issue 7, article e0005322
  24. Brooks RB, Walters M, Forsberg K, Vaeth E, Woodworth K, Vallabhaneni S. 鈥楥andida auris in a US patient with carbapenemase-producing organisms and recent hospitalization in Kenya鈥� Morbidity and Mortality Weekly Report 2019: volume 68, issue 30, pages 664 to 666
  25. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O and others. 鈥楪lobal guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM鈥� Lancet Infectious Diseases (published online 13 February 2025 ahead of print) (accessed on 1 March 2025)
  26. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L and others. 鈥楥linical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America鈥� Clinical Infectious Diseases 2016: volume 62, issue 4, pages e1 to e50
  27. Lionakis MS, Chowdhary A. 鈥楥andida auris infections鈥� New England Journal of Medicine 2024: volume 391, issue 20, pages 1,924 to 1,935
  28. Simon SP, Li R, Silver M, Andrade J, Tharian B, Fu L and others. 鈥楥omparative outcomes of Candida auris bloodstream infections: a multicenter retrospective case-control study鈥� Clinical Infectious Diseases 2023: volume 76, issue 3, pages e1436 to e1443
  29. Wake RM, Allebone-Salt PE, John LLH, Caswall BA, Govender NP, Ben-Ami R and others. 鈥極ptimizing the treatment of invasive Candidiasis-A case for combination therapy鈥� Open Forum Infectious Diseases 2024: volume 11, issue 6, article ofae072
  30. Balla N, Kovacs F, Balazs B, Borman AM, Bozo A, Jakab A and others. 鈥楽ynergistic interaction of caspofungin combined with posaconazole against FKS wild-type and mutant Candida auris planktonic cells and biofilms鈥� Antibiotics 2022: volume 11, issue 11 (no pagination)
  31. Fakhim H, Chowdhary A, Prakash A, Vaezi A, Dannaoui E, Meis JF and others. 鈥業n vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris鈥� Antimicrobial Agents and Chemotherapy 2017: volume 61, issue 11
  32. Jaggavarapu S, Burd EM, Weiss DS. 鈥楳icafungin and amphotericin B synergy against Candida auris鈥� The Lancet Microbe 2020: volume 1, issue 8, pages e314 to e315
  33. John LLH, Thomson DD, Bicanic T, Hoenigl M, Brown AJP, Harrison TS and others. 鈥楬eightened efficacy of Anidulafungin when used in combination with Manogepix or 5-Flucytosine against Candida auris in vitro鈥� Antimicrobial Agents and Chemotherapy 2023: artcle e0164522
  34. Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR. 鈥楶harmacodynamic optimization for treatment of invasive Candida auris infection鈥� Antimicrobial Agents and Chemotherapy 2017: volume 61, issue 8
  35. O鈥橞rien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. 鈥楶an-resistant Candida auris: New York subcluster susceptible to antifungal combinations鈥� Lancet Microbe 2020: volume 1, issue 5, pages e193 to e194
  36. Felton T, Troke PF, Hope WW. 鈥楾issue penetration of antifungal agents鈥� Clinical Microbiology Reviews 2014: volume 27, issue 1, pages 68 to 88
  37. Ham YY, Lewis JS, Thompson GR. 鈥楻ezafungin: A novel antifungal for the treatment of invasive candidiasis鈥� Future Microbiology 2021: volume 16, issue 1, pages 27 to 36
  38. Pfaller MA, Huband MD, Rhomberg PR, Bien PA, Castanheira M. 鈥楢ctivities of Manogepix and comparators against 1,435 recent fungal isolates collected during an international surveillance program (2020)鈥� 聽Antimicrobial Agents and Chemotherapy 2022: volume 66, issue 11, article e0102822
  39. Vazquez JA, Pappas PG, Boffard K, Paruk F, Bien PA, Tawadrous M and others. 鈥楥linical efficacy and safety of a novel antifungal, Fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial鈥� Antimicrobial Agents and Chemotherapy 2023: article e0141922
  40. Leroux S, Jacqz-Aigrain E, Elie V, Legrand F, Barin-Le Guellec C, Aurich B and others. 鈥楶harmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial鈥� British Journal of Clinical Pharmacology 2018: volume 84, issue 9, pages 1,989 to 1,999
  41. Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE and others. 鈥楾he pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates鈥� Journal of Infectious Diseases 2008: volume 197, issue 1, pages 163 to 171
  42. Kenters N, Kiernan M, Chowdhary A, Denning DW, Pem谩n J, Saris K and others. 鈥楥ontrol of Candida auris in healthcare institutions: outcome of an International Society for Antimicrobial Chemotherapy expert meeting鈥� International Journal of Antimicrobial Agents 2019: volume 54, issue 4, pages 400 to 406
  43. Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. 鈥業n vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris鈥� Mycoses 2017: volume 60, issue 11, pages 758 to 763
  44. Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS. 鈥榊easticidal activity of chemical disinfectants and antiseptics against Candida auris鈥� Journal of Hospital Infection 2017: volume 97, issue 4, pages 371 to 375
  45. Sherry L, Ramage G, Kean R, Borman A, Johnson EM, Richardson MD and others. 鈥楤iofilm-forming capability of highly virulent, multidrug-resistant Candida auris鈥� Emerging Infectious Diseases 2017: volume 23, issue 2, pages 328 to 331
  46. Omardien S, Teska P. 鈥楽kin and hard surface disinfection against Candida auris: what we know today鈥� Frontiers in Medicine 2024: volume 11, page 1,312,929
  47. Ghannoum M, Herrada J, McCormick TS, Long L. 鈥楢 novel transdermal application for clearing skin colonization by Candida auris鈥� Antimicrobial Agents and Chemotherapy 2021: volume 65, issue 5, pages e02303 to e02320
  48. Wei L, Li Y, Li X, Bian L, Wen Z, Li M. 鈥楥hlorhexidine-impregnated dressing for the prophylaxis of central venous catheter-related complications: a systematic review and meta-analysis鈥� BMC Infectious Diseases 2019: volume 19, issue 1, page 429
  49. Garcia-Bustos V, Salavert M, Ruiz-Gait谩n AC, Caba帽ero-Navalon MD, Sigona-Giangreco IA, Pem谩n J. 鈥楢 clinical predictive model of candidaemia by Candida auris in previously colonized critically ill patients鈥� Clinical Microbiology and Infection 2020: volume 26, issue 11, pages 1,507 to 1,513
  50. Shastri PS, Shankarnarayan SA, Oberoi J, Rudramurthy SM, Wattal C, Chakrabarti A. 鈥楥andida auris candidaemia in an intensive care unit: prospective observational study to evaluate epidemiology, risk factors, and outcome鈥� Journal of Critical Care 2020: volume 57, pages 42 to 48
  51. Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR and others. 鈥楥ore recommendations for antifungal stewardship: a statement of the Mycoses Study Group Education and Research Consortium鈥� Journal of Infectious Diseases 2020: volume 222, suplement 3, pages S175 to s98
  52. Whitney L, Al-Ghusein H, Glass S, Koh M, Klammer M, Ball J and others. 鈥楨ffectiveness of an antifungal stewardship programme at a London teaching hospital 2010 to 2016鈥� Journal of Antimicrobial Chemotherapy 2019: volume 74, issue 1, pages 234 to 241
  53. Micallef C, Ashiru-Oredope D, Hansraj S, Denning DW, Agrawal SG, Manuel RJ and others. 鈥楢n investigation of antifungal stewardship programmes in England鈥� Journal of Medical Microbiology 2017: volume 66, issue 11, pages 1,581 to 1,589
  54. Hart E, Nguyen M, Allen M, Clark CM, Jacobs DM. 鈥楢 systematic review of the impact of antifungal stewardship interventions in the United States鈥� Annals of Clinical Microbiology and Antimicrobials 2019: volume 18, issue 1, page 24
  55. Caceres DH, Forsberg K, Welsh RM, Sexton DJ, Lockhart SR, Jackson BR and others. 鈥楥andida auris: a review of recommendations for detection and control in healthcare settings鈥� Journal of Fungi 2019: volume 5, issue 4
  56. Ahmad S, Alfouzan W. 鈥楥andida auris: epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities鈥� Microorganisms 2021: volume 9, issue 4
  57. Chakrabarti A, Sood P. On the emergence, spread and resistance of Candida auris: host, pathogen and environmental tipping points鈥� Journal of Medical Microbiology 2021: volume 70, issue 3
  58. Yadav A, Singh A, Wang Y, Haren MHV, Singh A, de Groot T and others. 鈥楥olonisation and transmission dynamics of Candida auris among chronic respiratory diseases patients hospitalised in a chest hospital, Delhi, India: a comparative analysis of whole genome sequencing and microsatellite typing鈥� Journal of Fungi 2021: volume 7, issue 2
  59. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ and others. 鈥楽urvival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface鈥� Journal of Clinical Microbiology 2017: volume 55, issue 10, pages 2,996 to 3,005
  60. de Almeida JN, Jr., Francisco EC, Hagen F, Brand茫o IB, Pereira FM, Presta Dias PH and others, 鈥楨mergence of Candida auris in Brazil in a COVID-19 intensive care unit鈥� Journal of Fungi 2021: volume 7, issue 3
  61. Decker BK, Clancy CJ. 鈥楲anyards as source of a Candida auris outbreak: as you investigate the environment, do not overlook hand hygiene鈥� Critical Care Medicine 2021: pages 714 to 716
  62. Nobrega de Almeida J, Jr., Brand茫o IB, Francisco EC, de Almeida SLR, de Oliveira Dias P, Pereira FM and others. 鈥楢xillary digital thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil鈥� Mycoses 2021: volume 64, issue 9, pages 1,062 to 1,072
  63. Patterson CA, Patel A, Newsholme W, Tan M, Edgeworth JD, Wyncoll D and others. 鈥楥loth lanyards as a source of intermittent transmission of Candida auris on an ICU鈥� Critical Care Medicine 2021: pages 697 to 701
  64. CDC. 鈥樷�� (cited 11 August 2024)
  65. Weber DJ, Rutala WA, Sickbert-Bennett E. 鈥楨merging infectious diseases, focus on infection prevention, environmental survival and germicide susceptibility: SARS-CoV-2, Mpox, and Candida auris鈥� American Journal of Infection Control 2023: volume 51, issue 11s, pages a22 to a34
Back to top